Home › Funds › Rye Brook Capital LLC › PPH

Rye Brook Capital LLC position in PPH

VANECK PHARMACEUTICAL ETF

Rye Brook Capital LLC reported holding 70,255 shares of PPH (VANECK PHARMACEUTICAL ETF) in its Q3 2026 13F filing — a position valued at US$7.7M, representing 4.98% of its reported portfolio and ranking #5 among its reported holdings. Rye Brook Capital LLC has disclosed PPH holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)70.25K sh
Reported value held$7.69M
Portfolio Weight4.98%
First reportedQ2 2026
Last changeAdd
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How Rye Brook Capital LLC's PPH position evolved

Rye Brook Capital LLC first disclosed a stake in PPH in Q2 2026 at 67,330 shares (US$7.4M). The position peaked in Q3 2026 at 70,255 shares, worth US$7.7M. Across 2 filings, Rye Brook Capital LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 70,255 shares valued at US$7.7M — an increase of 2,925 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q2 2026 67.33K $7.36M New
Q3 2026 70.25K $7.69M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PPH and 13F data

PPH (VANECK PHARMACEUTICAL ETF) is a company whose sector is not yet classified in our data. 20 other funds we track also report a position in PPH — the largest reported positions include J.Safra Asset Management Corp (US$35.0M), Avalon Trust Co (US$28.8M), ADAMSBROWN WEALTH CONSULTANTS LLC (US$16.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PPH

All PPH fund holders →

FAQ

How long has Rye Brook Capital LLC held PPH?

Rye Brook Capital LLC has disclosed PPH holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Rye Brook Capital LLC's current position in PPH?

As of Q3 2026, Rye Brook Capital LLC holds 70.25K shares of PPH (VANECK PHARMACEUTICAL ETF), valued at $7.69M, representing 4.98% of its reported portfolio and ranking #5.

Has Rye Brook Capital LLC been buying or selling PPH?

In the latest 13F filing (Q3 2026), Rye Brook Capital LLC increased its position in PPH. The position peaked in Q3 2026 at 70.25K shares.

Which other funds hold PPH?

Other major institutional holders of PPH include J.Safra Asset Management Corp, Avalon Trust Co, ADAMSBROWN WEALTH CONSULTANTS LLC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.